All In Biotech

Drug Trial Radar · NCT02502968

BL-8040 Addition to Consolidation Therapy in AML Patients

A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients

Last checked: Nov 19, 2026Latest source record: Sep 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

194

Planned (sponsor's estimate)

Start

Sep 2015

Primary completion

Jul 2018

Sponsor

Lead sponsor
Dr. Petra TschanterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioLineRx, Ltd.
First posted
Jul 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the addition of BL-8040 to the standard consolidation therapy with cytarabine in the treatment of acute myeloid leukemia (AML) in adults. Half of participants will receive BL-8040 and cytarabine in combination, while the other half will receive placebo and cytarabine.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • CytarabineDrug

  • BL-8040Drug

  • Placebo (for BL-8040)Drug

    Powder for solution for injection manufactured to mimic BL-8040

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse Free Survival timeTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Univeritätsklinikum Halle, Klinik Innere Medizin 4

    Halle, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.